Patients in the olaparib arm experienced a 70% reduction in the risk of disease progression or death vs placebo.
The FDA granted approval to inotuzumab ozogamicin for the treatment of adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL).
After the second interim analysis, an external data monitoring committee recommended that pembrolizumab be made available to patients receiving ipilimumab whose disease had progressed despite treatment.
Atezolizumab monotherapy has a good overall response rate (ORR) and favorable safety profile in patients with advanced PD-L1 expressing non-small cell lung cancer (NSCLC).
Compared with ALK¬-positive patients, participants with ROS1 rearrangements were less likely to present with extrathoracic and brain metastases.
One (4.2%) patient achieved complete response, and 7 patients (29.2%) achieved durable partial responses. The overall response rate (ORR) was 33.3% (95% CI, 15.6%-55.3%).
At the median follow-up 22.9 months, 56.3% of patients in the BV arm achieved a significantly superior objective global response lasting at least 4 months vs 12.5% of patients in the IC arms.
Patients who were diagnosed early on in the study, or who received endocrine therapy or radical prostatectomy, exhibited a lower HR for mortality vs other patients with PC.
Given the comprehensiveness of LFR, the driver mutations and tissues of origin detected via this method may better guide treatment than most available gene panel-tests.
Among patients with R/R disease, 19.3% achieved complete remission (CR) and had a median overall survival of 19.7 months.
Patients with breast or lung cancer, fewer comorbidities, more advanced cancer, higher income and education, or who were younger or female were more likely to use AM.
Caregivers were also more likely to have greater care-related burden when patients reported requiring help with fewer IADLs than did the caregiver.
Researchers randomly assigned 124 patients to receive intravenous paclitaxel with ipatasertib or placebo.
The 1-year control rate was 99%, the 2-year control rate was 95%, and the median time to progression was 9 months.
Researchers are evaluating whether 6MHP, a peptide vaccine, is safe and efficacious when combined with ipilimumab in patients with stage IIIB or higher melanoma.
Researchers evaluated data from patients with prostate cancer to determine whether MFS or DFS are valid surrogate markers for OS.
Researchers enrolled 1418 patients with previously untreated DLBCL and randomly assigned them to receive G-CHOP or R-CHOP.
Researchers analyzed participant plasma specimens to determine whether EBV presence could effectively predict asymptomatic, early nasopharyngeal carcinoma.
Overall, 54% of patients in the non-adjuvant temozolomide arm had disease progression vs 39% of the adjuvant temozolomide arm.
In patients with R/R WM, the overall response rate was 87%, with 4% of patients achieving a very good partial response.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|